Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Biotechnology
|GILD||Gilead Sciences, Inc.||-0.19%||69.58||1.0%||$514.17m|
|VRTX||Vertex Pharmaceuticals, Inc.||0.09%||206.80||1.9%||$454.51m|
|REGN||Regeneron Pharmaceuticals, Inc.||0.00%||654.04||2.7%||$419.38m|
|SNSS||Sunesis Pharmaceuticals, Inc.||0.00%||4.36||0.7%||$304.78m|
|EXAS||EXACT Sciences Corp.||0.00%||86.26||18.0%||$150.95m|
|TXG||10X Genomics, Inc.||2.17%||155.41||0.0%||$140.47m|
Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia; KO-947 which is an ERK inhibitor for MAPK Pathway Tumors; and KO-539 which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in La Jolla, CA.